Molecular-Compute Commercialisation Board Examiner — Therapeutic Design

The mandate

Directors repeatedly confront the same question: when does a molecular computing demonstration become a repeatable design capability rather than an ingenious assay whose error, preparation labour and readout burden scale faster than useful computation? Partnership interest is rising, but benchmark claims combine wet-lab execution, algorithmic abstraction and therapeutic relevance in ways that the board cannot independently challenge.

The examiner will reserve two days monthly for evidence review, committee preparation and structured dialogue with scientific and partnering leaders, and attend five Zurich sessions. A short challenge note on a material replication or partner claim is due within two Swiss business days. Experimental work, technical diligence or transaction negotiation requires separate authorisation and scope.

The appointment runs for ten months from February 2027. During month eight, management will defend an unseen benchmark translation from laboratory run to partner economics. One three-month renewal may be approved by full-board vote for a named financing or collaboration decision; unused days expire and cannot be converted into programme delivery or continuing scientific supervision.

The examiner has no line authority, executive authority, laboratory authority, scientific-signing right, investment vote, product decision or partnership mandate. Management owns experiments and representations; the board decides capital; partners conduct their own diligence. Advice cannot be cited as validation of therapeutic efficacy, molecular-compute advantage, patentability or manufacturing feasibility.

Appointments or interests involving molecular-computing ventures, synthetic-biology platforms, laboratory suppliers, therapeutic partners, investors or benchmark publishers must be disclosed as conflicts. The examiner may retain one non-competing scientific board role with chair approval. Equity in a direct competitor or contingent compensation linked to a transaction under review is disqualifying.

Why the board wants this voice

The room contains accomplished molecular scientists and investors, but no director has carried an unconventional computing platform from elegant proof through reproducible operations and partner scrutiny. The board wants someone able to separate computational novelty, experimental fidelity and commercial leverage without becoming another promoter, scientist of record or deal sponsor.

What you will own

• Press directors to separate encoded problem, molecular preparation, reaction, readout, error correction, interpretation and therapeutic-use evidence.
• Test benchmark comparisons for hidden laboratory labour, failed-run selection, reagent consumption, latency and conventional-compute dependence.
• Challenge scaling assumptions around addressability, cross-talk, contamination, read accuracy, automation yield and reproducibility between sites.
• Frame scenarios involving partner replication failure, changed assay chemistry, disputed baseline, supplier discontinuation and unplanned error growth.
• Probe whether intellectual-property and data-right positions survive reliance on academic protocols, external laboratories and partner materials.
• Examine investment gates through reproducibility, useful problem class, operating cost, partner pull and evidence needed to abandon a path.
• Coach directors to request decision-grade uncertainty rather than a single performance ratio or visually persuasive demonstration.

Candidate qualifications

• Held senior platform, research translation or venture-governance responsibility in molecular computation, synthetic biology or unconventional life-science computing.
• Evaluated full experimental workloads spanning encoding, preparation, reaction, readout, error correction and conventional computational support.
• Challenged benchmark claims after cross-site replication, contamination, yield or assay changes altered the apparent computing advantage.
• Brought frontier research through pharmaceutical or biotechnology partnership diligence without overstating therapeutic or manufacturing readiness.
• Presented capital-stop, replication and platform-focus choices to science-intensive boards facing scarce evidence and enthusiastic external narratives.
• Managed conflicts across ventures, laboratories, investors, suppliers and therapeutic partners while protecting unpublished methods and results.

Non-negotiables

• Can attend all five Zurich sessions and provide two-business-day challenge during a declared replication or partnership event.
• Will disclose every relevant venture, laboratory, supplier, investor, benchmark and therapeutic-partner interest before evidence access.
• Accepts literal absence of line, executive, scientific, laboratory, investment, product and transaction authority.
• Must evidence a frontier-compute replication or scale decision; general biotechnology investing or computational biology is insufficient.

1. 49 words maximum. Describe a molecular or biological compute benchmark that weakened when full experimental work was counted.
2. 49 words maximum. Which current venture, laboratory, supplier, investor or therapeutic interests require board disclosure?
3. 49 words maximum. What evidence would make you recommend stopping a technically novel molecular-compute path?